Regulation & law · 11/12/2024Updated: 10/16/2026 · 1 min read
National Cancer Institute to Grant Exclusive Patent License to StraightLine Bio for Cancer Treatment
Summary
The National Cancer Institute (NCI) is considering granting an exclusive patent license to StraightLine Bio, Inc. for the use of anti-KK-LC-1 T cell receptors in cancer treatment.
Original source language: Federal Register — All DocumentsOpen original release →